Last reviewed · How we verify

NCT06297538

Parkinson's Disease and Gamma-transcranial Alternating Current Stimulation

Recruiting now NA Last updated 7 March 2024
What this trial tests

NA trial testing gamma transcranial alternating current stimulation (tACS) in Parkinson Disease in 84 participants. Currently enrolling.

Timeline
29 April 2023
Primary endpoint
29 October 2024
29 April 2026

Quick facts

Lead sponsorNeuromed IRCCS
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment84
Start date29 April 2023
Primary completion29 October 2024
Estimated completion29 April 2026
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Neuromed IRCCS

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cortical-basal ganglia gamma oscillations are pathologically reduced in Parkinson's disease (PD) and the plasticity of the primary motor cortex (M1) is impaired. Enhancing gamma oscillations through transcranial alternating current stimulation (tACS), a non-invasive neurophysiological tool that modulates cortical rhythms, can restore this alteration. However, whether tACS-related normalization of M1 plasticity results in positive clinical effects is unknown. Motor learning is also impaired in PD and gamma oscillations play a relevant role in different forms of learning in humans. Nevertheless, whether motor learning abnormalities relate to reduced gamma oscillations in PD is another unclear issue. It can be hypothesized that gamma oscillations impairment in M1 contributes to altered motor control, plasticity and learning in PD. Accordingly, in this project, the authors intend to test whether gamma-tACS on M1 in PD patients ameliorates motor performance and learning, as objectively assessed with kinematic techniques.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Driving motor cortex oscillations restores plasticity and improves bradykinesia features in Parkinson's disease.
    Paparella G, Costa D, De Riggi M, Angelini L, et al · · 2026 · PMID 42115691 · DOI 10.1038/s41531-026-01373-0

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other Neuromed IRCCS trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06297538.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing